Summary & Overview
HCPCS Level II J1834: Injection, isoniazid, 1 mg
HCPCS Level II code J1834 denotes a 1 mg injectable dose of isoniazid, an anti-tuberculosis agent used in clinical settings where parenteral administration is required. This code is important for accurate billing and inventory tracking of injectable isoniazid across ambulatory and hospital outpatient settings. Nationally, correct use of J1834 supports proper reimbursement, clinical documentation, and public health reporting where injectable therapy is part of tuberculosis management.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J1834 represents, typical sites of service, and the clinical context for injectable isoniazid. The publication highlights benchmarks and policy-relevant considerations for billing and coding of injectable medications, outlines common modifiers used with medication administration claims, and identifies areas where data was not provided.
This summary provides clinicians, billing specialists, and policy analysts with the essential information needed to recognize the proper use of HCPCS Level II code J1834, understand payer coverage scope at a national level, and locate more detailed sections on coding nuances, reimbursement benchmarks, and clinical context.
Billing Code Overview
HCPCS Level II code J1834 represents an injection of isoniazid, 1 mg. The service is the administration of the anti-tuberculosis medication isoniazid in an injectable form, typically billed per milligram.
Service Type: Medication administration (injectable pharmacologic agent)
Typical Site of Service: Outpatient clinic, hospital outpatient department, infusion center, or other ambulatory settings where injectable medications are administered. Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult undergoing treatment or post-exposure management for latent or active tuberculosis who requires direct administration of isoniazid. The patient presents to an outpatient infectious disease clinic, public health clinic, or primary care office for medication administration and adherence counseling. The clinical workflow includes verification of indication and allergies, baseline liver function testing and review of prior laboratory results, patient counseling about hepatotoxicity and peripheral neuropathy, administration of J1834 (isoniazid) by intramuscular or intradermal injection when indicated, observation for immediate adverse reaction, documentation of lot number and expiration, and scheduling of follow-up monitoring visits. Typical sites of service include outpatient clinics, public health departments, and long-term care facilities where nursing staff or qualified clinicians administer the medication. Patient scenarios include latent tuberculosis infection requiring directly observed therapy (DOT), post-exposure prophylaxis after a confirmed TB exposure, or circumstances where oral administration is not feasible and an injectable formulation is used for adherence or clinical reasons.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | When no additional modifier is applicable for the service |